The DIRECT Consortium and REST-meta-MDD Project: Towards Neuroimaging Guided Precision Treatment of Major Depression
Tue, May 14
|Virtual event
This 1-hour presentation will cover: (1) The establishment of the Depression Imaging REsearch ConsorTium (DIRECT) .(2) Outcomes from DIRECT Phase II, highlighting the roles of the sgACC and left DLPFC, vital for TMS outcomes. (3) Plans for multi-site clinical trials in DIRECT Phase III.
Time & Location
May 14, 2024, 6:00 p.m. – 7:00 p.m. PDT
Virtual event
Guests
About the event
Speaker: Dr Chao-Gan Yan, Professor at the Institute of Psychology, Chinese Academy of Sciences
Moderator: Dr Ruiyang Ge, University of British Columbia
Despite a growing neuroimaging literature on the pathophysiology of major depressive disorder (MDD), reproducible findings are lacking, likely reflecting mostly small sample sizes and heterogeneity in analytic approaches. To address these issues, the Depression Imaging REsearch ConsorTium (DIRECT) was launched.
DIRECT Phase I pooled 2428 functional brain images processed with a standardized pipeline across all participating sites for the REST-meta-MDD project.
DIRECT Phase II used a state-of-the-art, surface-based preprocessing pipeline to improve sensitivity. This time we focused on the subgenual anterior cingulate cortex (sgACC), which plays a central role in the pathophysiology of major depressive disorder (MDD), and its functional interactive profile with the left dorsal lateral prefrontal cortex (DLPFC) is associated with transcranial magnetic stimulation (TMS) treatment outcomes.
Leveraging the Phase II large multi-site sample (1660 MDD…